soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Canadian Perspectives 2025 Whiteboard on

Regular check-ups and blood tests can determine if there is a deficiency

Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

Novo Nordisk holds patents on semaglutide that extend through approximately 2032, preventing generic manufacturers from producing equivalent versions

Goals and Objectives of the Program The primary goals of the Wegovy PAP are to: Provide access to Wegovy for eligible patients who cannot afford the medication

Many transgender persons have reported significant levels of depression, anxiety, social isolation, and even suicidal ideation